![Robert P. Ryan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert P. Ryan
Algemeen Directeur bij Innova Therapeutics, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Alistair Duncan | M | - |
viDA Therapeutics, Inc.
![]() viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | 16 jaar |
Robert Williamson | M | 58 |
Aegle Therapeutics Corp.
![]() Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | 11 jaar |
Evangelos V. Badiavas | M | - |
Aegle Therapeutics Corp.
![]() Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | 11 jaar |
David Granville | M | - |
viDA Therapeutics, Inc.
![]() viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | 16 jaar |
Brett Kopelan | M | - |
Dystrophic Epidermolysis Bullosa Rsch Assoc of America, Inc.
| - |
Shelley A. Hartman | F | - |
Aegle Therapeutics Corp.
![]() Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | - |
Julia G. Levy | M | 89 |
viDA Therapeutics, Inc.
![]() viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
Vicki L. Morgan | F | - |
viDA Therapeutics, Inc.
![]() viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
Donald W. Campbell | M | 83 |
viDA Therapeutics, Inc.
![]() viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
Lonnie Moulder | M | 66 |
Aegle Therapeutics Corp.
![]() Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | - |
David Pittaway | M | 72 |
Dystrophic Epidermolysis Bullosa Rsch Assoc of America, Inc.
| - |
Marlene Haffner | M | 83 |
viDA Therapeutics, Inc.
![]() viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
Heidi Kempinski | F | - |
Aegle Therapeutics Corp.
![]() Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | 4 jaar |
Dominque Bélanger | M | - |
viDA Therapeutics, Inc.
![]() viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
Elona Baum | F | - |
Aegle Therapeutics Corp.
![]() Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | - |
Gosse Bote Bruinsma | M | 69 |
viDA Therapeutics, Inc.
![]() viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
David Schimel | M | - |
Aegle Therapeutics Corp.
![]() Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Nigel Johnson | M | - | 14 jaar | |
Melanie Farris | F | - | 5 jaar | |
John Michailidis | M | - | 4 jaar | |
Rosalind Wilson | M | - | 2 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 9 | 42.86% |
Canada | 8 | 38.10% |
Australië | 4 | 19.05% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Robert P. Ryan
- Persoonlijk netwerk